David H. Ellison

David H. Ellison

Auto-generated profile, based on publicly available information

David H. Ellison

Division of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, Oregon

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1996 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DSDavid B. Simon
David B. Simon
CNCarol Nelson-Williams
Carol Nelson-Williams
MBMargaret Johnson Bia
Margaret Johnson Bia
DEDavid Ellison
David Ellison
FFFiona E. Karet Frankl
Fiona E. Karet Frankl
RLRichard P. Lifton
Richard P. Lifton

17 May 2007 in New England Journal of Medicine
Verified
Journal Article
Closed access
DEDavid H. Ellison
David H. Ellison
TBTomas Berl
Tomas Berl
A 62-year-old woman who reported dysgeusia was found to have a serum sodium level of 122 mmol per liter. The serum osmolality was 250 mOsm per kilogram of water, and the urinary osmolality 635 mOsm per kilogram of water. Chest CT showed a mass in the lower lobe of the left lung, which proved to be a small-cell carcinoma. How should her hyponatremia be treated?

1 January 2015 in Cell Metabolism
Verified
Journal Article
Closed access
ATAndrew S. Terker
Andrew S. Terker
CZChong Zhang
Chong Zhang
JMJames McCormick
James McCormick
RLRebecca A. Lazelle
Rebecca A. Lazelle
CZChengbiao Zhang
Chengbiao Zhang
DEDavid H. Ellison
David H. Ellison

2 October 2011 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EHEwout J Hoorn
Ewout J Hoorn
SWStephen B Walsh
Stephen B Walsh
JMJames McCormick
James McCormick
AFAntje Fürstenberg
Antje Fürstenberg
CYChao-Ling Yang
Chao-Ling Yang
DEDavid H Ellison
David H Ellison
Calcineurin inhibitors, such as tacrolimus, are widely used immunosuppressive agents, but they can cause hypertension. In studies of tacrolimus-treated mice, the authors show that hypertension is due to activation of the sodium chloride transporter NCC in the kidney, causing sodium retention. They found that NCC activation also occurred in kidney transplant recipients receiving tacrolimus. The authors suggest that thiazide diuretics, which are NCC inhibitors, might counteract the hypertensive effects of this class of immunosuppressants. Calcineurin inhibitors (CNIs) are immunosuppressive drugs that are used widely to prevent rejection of transplanted organs and to treat autoimmune disease. Hypertension and renal tubule dysfunction, including hyperkalemia, hypercalciuria and acidosis, often complicate their use1,2. These side effects resemble familial hyperkalemic hypertension, a genetic disease characterized by overactivity of the renal sodium chloride cotransporter (NCC) and caused by mutations in genes encoding WNK kinases. We hypothesized that CNIs induce hypertension by stimulating NCC. In wild-type mice, the CNI tacrolimus caused salt-sensitive hypertension and increased the abundance of phosphorylated NCC and the NCC-regulatory kinases WNK3, WNK4 and SPAK. We demonstrated the functional importance of NCC in this response by showing that tacrolimus did not affect blood pressure in NCC-knockout mice, whereas the hypertensive response to tacrolimus was exaggerated in mice overexpressing NCC. Moreover, hydrochlorothiazide, an NCC-blocking drug, reversed tacrolimus-induced hypertension. These observations were extended to humans by showing that kidney transplant recipients treated with tacrolimus had a greater fractional chloride excretion in response to bendroflumethiazide, another NCC-blocking drug, than individuals not treated with tacrolimus; renal NCC abundance was also greater. Together, these findings indicate that tacrolimus-induced chronic hypertension is mediated largely by NCC activation, and suggest that inexpensive and well-tolerated thiazide diuretics may be especially effective in preventing the complications of CNI treatment.

1 January 2017 in Kidney International
Verified
Journal Article
Open access
ABAnne Blanchard
Anne Blanchard
DBDetlef Bockenhauer
Detlef Bockenhauer
Davide BolignanoDavide Bolignano
Davide Bolignano
LCLorenzo A. Calò
Lorenzo A. Calò
ECEtienne Cosyns
Etienne Cosyns
RVRosa Vargas-Poussou
Rosa Vargas-Poussou
Gitelman syndrome (GS) is a rare, salt-losing tubulopathy characterized by hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria. The disease is recessively inherited, caused by inactivating mutations in the SLC12A3 gene that encodes the thiazide-sensitive sodium-chloride cotransporter (NCC). GS is usually detected during adolescence or adulthood, either fortuitously or in association with mild or nonspecific symptoms or both. The disease is characterized by high phenotypic variability and a significant reduction in the quality of life, and it may be associated with severe manifestations. GS is usually managed by a liberal salt intake together with oral magnesium and potassium supplements. A general problem in rare diseases is the lack of high quality evidence to inform diagnosis, prognosis, and management. We report here on the current state of knowledge related to the diagnostic evaluation, follow-up, management, and treatment of GS; identify knowledge gaps; and propose a research agenda to substantiate a number of issues related to GS. This expert consensus statement aims to establish an initial framework to enable clinical auditing and thus improve quality control of care.

10 September 2006 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MLMaria D Lalioti
Maria D Lalioti
JZJunhui Zhang
Junhui Zhang
HVHeather M Volkman
Heather M Volkman
KKKristopher T Kahle
Kristopher T Kahle
KHKristin E Hoffmann
Kristin E Hoffmann
RLRichard P Lifton
Richard P Lifton